Genscript Biotech Corporation (G51) - Total Liabilities

Latest as of December 2025: €888.59 Million EUR ≈ $1.04 Billion USD

Based on the latest financial reports, Genscript Biotech Corporation (G51) has total liabilities worth €888.59 Million EUR (≈ $1.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Genscript Biotech Corporation - Total Liabilities Trend (2016–2025)

This chart illustrates how Genscript Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. See Genscript Biotech Corporation working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Genscript Biotech Corporation Competitors by Total Liabilities

The table below lists competitors of Genscript Biotech Corporation ranked by their total liabilities.

Company	Country	Total Liabilities
Graphic Packaging Holding Company NYSE:GPK	USA	$8.44 Billion
Cal-Comp Electronics (Thailand) Public Company Limited TW:9105	Taiwan	NT$52.32 Billion
Asker Healthcare ST:ASKER	Sweden	Skr10.88 Billion
Zhejiang XinAn Chemical Industrial Group Co Ltd SHG:600596	China	CN¥8.28 Billion
Zealand Pharma A/S CO:ZEAL	Denmark	Dkr1.63 Billion
Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco F:RJ8	Germany	€596.51 Million
SF Diamond SHE:300179	China	CN¥895.22 Million
Mangalore Refinery and Petrochemicals Limited NSE:MRPL	India	Rs222.43 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Genscript Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see G51 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.50	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.22	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genscript Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genscript Biotech Corporation (2016–2025)

The table below shows the annual total liabilities of Genscript Biotech Corporation from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€888.59 Million ≈ $1.04 Billion	-6.95%
2024-12-31	€954.91 Million ≈ $1.12 Billion	-28.89%
2023-12-31	€1.34 Billion ≈ $1.57 Billion	+13.45%
2022-12-31	€1.18 Billion ≈ $1.38 Billion	+3.85%
2021-12-31	€1.14 Billion ≈ $1.33 Billion	+80.40%
2020-12-31	€631.82 Million ≈ $738.66 Million	+22.18%
2019-12-31	€517.11 Million ≈ $604.56 Million	+22.05%
2018-12-31	€423.68 Million ≈ $495.32 Million	+53.54%
2017-12-31	€275.94 Million ≈ $322.61 Million	+556.84%
2016-12-31	€42.01 Million ≈ $49.12 Million	--

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$3.14 Billion

€2.69 Billion EUR

Market Cap Rank

#4879 Global

#807 in Germany

Share Price

€1.23

Change (1 day)

-3.91%

52-Week Range

€1.14 - €2.04

All Time High

€4.62